首页> 外文期刊>Trials >Efficacies of the new Paclitaxel-eluting Coroflex Please? Stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please? and Taxus? (ECO-PLEASANT) trial: study rationale and design
【24h】

Efficacies of the new Paclitaxel-eluting Coroflex Please? Stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please? and Taxus? (ECO-PLEASANT) trial: study rationale and design

机译:新型紫杉醇洗脱Coroflex的功效好吗?经皮冠状动脉介入治疗的支架;比较Coroflex的功效吗?和红豆杉? (ECO-PLEASANT)试用:研究基本原理和设计

获取原文
           

摘要

Background Previous randomized trials have showed the superiority of Paclitaxel-eluting stent over bare metal stent in angiographic and clinical outcomes. Coroflex Please? stent is a newly developed drug eluting stent using the Coroflex? stent platform combined with the drug paclitaxel contained in a polymer coating. PECOPS I trial, one-arm observational study, showed that the clinical and angiographic outcomes of Coroflex Please? stent were within the range of those of Taxus, the 1st generation paclitaxel-eluting stent (PES). However, there have been no studies directly comparing the Coroflex Please? stent with the Taxus Liberte? stent that is the newest version of Taxus. Therefore, prospective, randomized trial is required to demonstrate the non-inferiority of Coroflex Please? stent compared with Taxus Liberte? stent in a head-to-head manner. Methods In the comparison of Efficacy between COroflex PLEASe? ANd Taxus? stent(ECO-PLEASANT) trial, approximately 900 patients are being prospectively and randomly assigned to the either type of Coroflex Please? stent and Taxus Liberte? stent via web-based randomization. The primary endpoint is clinically driven target vessel revascularization at 9 months. The secondary endpoints include major cardiac adverse events, target vessel failure, stent thrombosis and angiographic efficacy endpoints. Discussion The ECO-PLEASANT trial is the study not yet performed to directly compare the efficacy and safety of the Coroflex Please? versus Taxus Liberte? stent. On the basis of this trial, we will be able to find out whether the Coroflex Please? stent is non-inferior to Taxus Liberte? stent or not. Trial registration ClinicalTrials.gov number, NCT00699543.
机译:背景以前的随机试验显示,在血管造影和临床结果方面,紫杉醇洗脱支架优于裸金属支架。请问Coroflex?支架是使用Coroflex?的新开发的药物洗脱支架。支架平台与聚合物涂层中包含的紫杉醇药物结合。 PECOPS I试验(单臂观察性研究)显示Coroflex的临床和血管造影结果如何?第1代紫杉醇洗脱支架(PES)的Taxus支架在其范围之内。但是,还没有直接比较Coroflex的研究吗?支架与Taxus Liberte?支架是Taxus的最新版本。因此,需要进行前瞻性随机试验以证明Coroflex的非劣效性吗?支架与Taxus Liberte相比?头对头支架。方法比较COroflex PLEASe?的疗效。和红豆杉?支架(ECO-PLEASANT)试验,大约有900名患者被随机分配到两种类型的Coroflex中?支架和Taxus Liberte?通过基于网络的随机分配支架。主要终点是9个月时临床驱动的靶血管血运重建。次要终点包括主要的心脏不良事件,靶血管衰竭,支架血栓形成和血管造影功效终点。讨论是否正在进行ECO-PLEASANT试验以直接比较Coroflex的疗效和安全性?与Taxus Liberte?支架。在此试验的基础上,我们将能够找出Coroflex Please吗?支架不逊于Taxus Liberte?支架与否。试用注册ClinicalTrials.gov编号,NCT00699543。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号